XL t(14;18) IGH/BCL2 DF

Translocation/Dual Fusion Probe

Order Number
Package Size
100 µl (10 Tests)


XL t(14;18) IGH/BCL2 DF

XL t(14;18) IGH/BCL2 DF is designed as a dual fusion probe. The orange labeled probe spans the breakpoint at 18q21 (BCL2), the green labeled probe flanks the IGH breakpoint region at 14q32.

Need Help?

Clinical Details

Rearrangements of the immunoglobulin heavy chain (IGH) gene locus are present in about 50% of all Non-Hodgkin lymphomas (NHL) including follicular lymphomas (FL) and diffuse large B-cell lymphomas (DLBCL). The FL is the most common indolent form of NHL and accounts for about 20%-30% of all lymphoid tumors. The reciprocal translocation t(14;18)(q32;q21) can be detected in about 85% of patients with FL and in up to 35% of patients with DLBCL. t(14;18) juxtaposes BCL2 to transcriptional enhancers in the IGH locus and results in overexpression of the BCL-2 protein in neoplastic follicles. BCL2 is involved in the regulation of programmed cell death and shows anti-apoptotic characteristics. Overexpression of BCL2 leads to a high number of B cells having a prolonged lifespan in germinal centers. This increases the chance to acquire additional chromosomal alterations required for the neoplastic transformation of B cells. Secondary mutations promoting the transformation process are among others t(14;18) and the deletion of the TP53 and CDKN2A genes.

Clinical Applications

  • Non-Hodgkin Lymphomas (NHL)
Need Help?


XL t(14;18) IGH/BCL2 DF

XL t(14;18) IGH/BCL2 DF hybridized to lymphocytes. One normal interphase and metaphase are shown.

Need Help?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.

Need Help?


  • Bernicot et al (2005) Anticancer Res 25:3179-3182
  • Ott and Rosenwald (2008) Haemotologica 93:1773-1776
  • Freedman (2014) Am J Hematol 89: 429-436